Research location
Catania
Catania, Italy
Advertisement
Research activity in Catania
Catania, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 14 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Catania
14 linked trials · page 1 of 1NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast CancerNCT06259929 · 2025-01-27 · 1 site observation
RECRUITING
Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung LesionsNCT07401615 · 2024-11-25 · 1 site observation
RECRUITING
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNCT07128199 · 2025-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)NCT06018337 · 2024-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF StudyNCT04331769 · 2020-12-21 · 1 site observation
SUSPENDED
Comparison of CRT-D and CRT-DX Systems (CRT-NEXT)NCT03587064 · 2018-10-22 · 1 site observation
COMPLETED
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)NCT02776072 · 2016-05-01 · 1 site observation
COMPLETED
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · 2015-02-24 · 1 site observation
COMPLETED
Trazodone Once a Day in Major Depression DisorderNCT02086929 · 2012-12-01 · 1 site observation
COMPLETED
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisNCT01064401 · 2010-05-01 · 1 site observation
COMPLETED
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisNCT01058005 · 2010-03-01 · 1 site observation
TERMINATED
Overcoming Endocrine Resistance in Metastatic Breast CancerNCT02394496 · 2007-11-01 · 3 site observations
UNKNOWN
Preventing ESRD in Overt Nephropathy of Type 2 DiabetesNCT00494715 · 2007-05-01 · 1 site observation
COMPLETED
Statins in Proteinuric NephropathiesNCT00199927 · 2003-03-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.